Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

European Journal of Cancer

Volumn 75, Issue , 2017, Pages 47-55

  Zimmer, Lisa ^a   Apuri, Susmitha ^b   Eroglu, Zeynep ^b   Kottschade, Lisa A ^c   Forschner, Andrea ^d   Gutzmer, Ralf ^e   Schlaak, Max ^f   Heinzerling, Lucie ^g   Krackhardt, Angela M ^h   Loquai, Carmen ⁱ   Markovic, Svetomir N ^c   Joseph, Richard W ^c   Markey, Kelly ^b   Utikal, Jochen S ^j,k   Weishaupt, Carsten ^l   Goldinger, Simone M ^m   Sondak, Vernon K ^b   Zager, Jonathan S ^b   Schadendorf, Dirk ^a   Khushalani, Nikhil I ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^j GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^m UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Anti PD 1; Disease progression; Efficacy; Ipilimumab; Ipilimumab and nivolumab; Melanoma; Nivolumab; Pembrolizumab; Treatment failure

Indexed keywords

IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; ANTINEOPLASTIC AGENT; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; SKIN NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85012949946     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.01.009     Document Type: Article

References (26)

1. [1] Atkins, M.B., Larkin, J., Immunotherapy combined or sequenced with targeted therapy in the treatment of solid tumors current perspectives. J Natl Cancer Inst, 108(6), 2016 djv414.
2. [2] Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M., Chen, L., Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 7:2 (2007), 95–106.
3. [3] Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:4 (2015), 375–384.
4. [4] Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:8 (2015), 908–918.
5. [5] Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:26 (2011), 2517–2526.
6. [6] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
7. [7] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
8. [8] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
9. [9] Shin, D.S., Zaretsky, J.M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov, 2016 Nov 30 pii: CD-16-1223. [Epub ahead of print].
10. [10] Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375:9 (2016), 819–829.
11. [11] Koyama, S., Akbay, E.A., Li, Y.Y., Herter-Sprie, G.S., Buczkowski, K.A., Richards, W.G., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun, 7, 2016, 10501.
12. [12] Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J Clin Oncol 33:17 (2015), 1974–1982.
13. [13] Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A.J., et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res 4:4 (2016), 345–353.
14. [14] Robert, C., Ribas, A., Wolchok, J.D., Hodi, F.S., Hamid, O., Kefford, R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384:9948 (2014), 1109–1117.
15. [15] Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., et al. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 114:10 (2016), 1084–1089.
16. [16] Jacobsoone-Ulrich, A., Jamme, P., Alkeraye, S., Dzwiniel, V., Faure, E., Templier, C., et al. Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases. Melanoma Res 26:2 (2016), 153–156.
17. [17] Aya, F., Gaba, L., Victoria, I., Fernandez-Martinez, A., Tosca, M., Prat, A., et al. Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. Future Oncol 12:23 (2016), 2683–2688.
18. [18] Long, G.V., Robert, C., Blank, C.U., Ribas, A., Mortier, L., Schachter, J., et al. Outcomes in patients (pts) treated with ipilimumab (ipi) after pembrolizumab (pembro) in KEYNOTE-006. Pigment Cell Melanoma Res, 30(1), 2017, 118.
19. [19] Balch, C.M., Gershenwald, J.E., Soong, S.J., Thompson, J.F., Atkins, M.B., Byrd, D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:36 (2009), 6199–6206.
20. [20] Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:2 (2009), 228–247.
21. [21] Kirchberger, M.C., Hauschild, A., Schuler, G., Heinzerling, L., Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. Eur J Cancer 65 (2016), 182–184.
22. [22] Weide, B., Martens, A., Hassel, J.C., Berking, C., Postow, M.A., Bisschop, K., et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22:22 (2016), 5487–5496.
23. [23] Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R.R., Hospers, G.A., van den Eertwegh, A.J., et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63:5 (2014), 449–458.
24. [24] Nakamura, Y., Kitano, S., Takahashi, A., Tsutsumida, A., Namikawa, K., Tanese, K., et al. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. Oncotarget 7:47 (2016), 77404–77415.
25. [25] Diem, S., Kasenda, B., Martin-Liberal, J., Lee, A., Chauhan, D., Gore, M., et al. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer 51:18 (2015), 2785–2791.
26. [26] Long, G.V., Grob, J.-J., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17:12 (2016), 1743–1754.